Adherence with tobramycin inhaled solution and health care utilization
نویسندگان
چکیده
BACKGROUND Adherence with tobramycin inhalation solution (TIS) during routine cystic fibrosis (CF) care may differ from recommended guidelines and affect health care utilization. METHODS We analyzed 2001-2006 healthcare claims data from 45 large employers. Study subjects had diagnoses of CF and at least 1 prescription for TIS. We measured adherence as the number of TIS therapy cycles completed during the year and categorized overall adherence as: low ≤ 2 cycles, medium >2 to <4 cycles, and high ≥ 4 cycles per year. Interquartile ranges (IQR) were created for health care utilization and logistic regression analysis of hospitalization risk was conducted by TIS adherence categories. RESULTS Among 804 individuals identified with CF and a prescription for TIS, only 7% (n = 54) received ≥ 4 cycles of TIS per year. High adherence with TIS was associated with a decreased risk of hospitalization when compared to individuals receiving ≤ 2 cycles (adjusted odds ratio 0.40; 95% confidence interval 0.19-0.84). High adherence with TIS was also associated with lower outpatient service costs (IQR: $2,159-$8444 vs. $2,410-$14,423) and higher outpatient prescription drug costs (IQR: $35,125-$60,969 vs. $10,353-$46,768). CONCLUSIONS Use of TIS did not reflect recommended guidelines and may impact other health care utilization.
منابع مشابه
Author ' s response to reviews Title : Adherence with tobramycin inhaled solution and health care utilization
متن کامل
Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data
PURPOSE Tobramycin inhalation powder (TIP), the first dry-powder inhaled antibiotic for pulmonary Pseudomonas aeruginosa infection, is associated with reduced treatment burden, increased patient satisfaction, and higher self-reported adherence for cystic fibrosis (CF) patients. We compared adherence in CF patients newly treated with TIP with those newly treated with the traditional tobramycin i...
متن کاملAcute renal failure associated with inhaled tobramycin.
PURPOSE A case of nephrotoxicity possibly caused by tobramycin inhalation solution is presented. SUMMARY A 62-year-old Caucasian woman was admitted for treatment of decreased urine output and sepsis secondary to Pseudomonas aeruginosa. Her past medical history was significant for multiple diseases, including chronic renal insufficiency (baseline serum creatinine concentration [SCr] 2 mg/dL). ...
متن کاملAdherence to the 2007 cystic fibrosis pulmonary guidelines: a national survey of CF care centers.
OBJECTIVE To examine cystic fibrosis (CF) physician adherence to the 2007 CF Foundation (CFF) Pulmonary Guidelines for Chronic Medications. Specifically adherence and barriers to prescribing level A medication recommendations (i.e., inhaled tobramycin and dornase alfa) and level B medication recommendations (i.e., macrolide antibiotics and hypertonic saline) were studied. METHODS During Sprin...
متن کاملIN THIS ISSUE COMMENTARY Comparing Inhaled Aztreonam to Tobramycin Cost Effectiveness of Aztreonam Lysine Inhaled Tobramycin Affected by Chronic Azithromycin Use AZLI Use: Three Year Prevalence Changes Comparing Colistimethate Sodium Dry Powder to Inhaled Tobramycin Program Directors
Pseudomonas aeruginosa colonization of the cystic fibrosis airway requires chronic therapy with inhaled antibiotics for nearly all patients. Clinician options in the US, however, are limited to tobramycin nebulizer solution (TNS) and aztreonam for inhalation solution (AZLI); in the EU and many other parts of the world, colistimethate and colistimethate dry powder for inhalation (CDPI) are also ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 11 شماره
صفحات -
تاریخ انتشار 2011